September 18, 2024 NeoGenomics Lung SolutionNeoGenomics’ lung solution supports the care continuum with profiles that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options. We meet you and your patient where they are, whether they are in an early or advanced stage or when there is no tissue.
NEO | Early-stage NSCLC The first and only therapy selection panel designed specifically for your early-stage patient. This panel provides actionable information based on guideline approved therapies in as little as 7 days.
NEO | InVisionFirst™ - Lung A liquid biopsy assay that detects 37 genes relevant to the treatment and management of NSCLC. Use at progression for patients progressing on or after chemotherapy or immunotherapy, and for patients progressing on EGFR tyrosine kinase inhibitors (TKIs). Timely results delivered within 7 days.
NEO | Comprehensive™- Solid Tumor is a wide-spectrum panel that screens genetic markers beyond those found in cancer-specific profiles in order to identify less frequent markers that smaller cancer specific profiles could miss. This panel sequences 517 genes by DNA and RNA next-generation sequencing. Results delivered in 8-10 days.
We don’t expect you to put your patients’ cancer questions in the hands of just anyone. For over 20 years, we set the standard for quality, accurate, and reliable solutions to deliver precise answers that you know you can trust.
|